Role of the amygdala and possible biomarkers in psychiatric disorders
NeuroMarkers, ISSN: 2950-5887, Vol: 2, Issue: 1, Page: 100032
2025
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Review Description
In the early 1800s, the "cerebral amygdala" was described as an almond-shaped structure within the temporal lobe. A century later, the role of amygdala in modulating behavior became evident, specifically in social and emotional features. This discovery established the amygdala as a critical component of the limbic system and essential for emotion regulation. Its connections with the hippocampus, prefrontal cortex, and hypothalamus highlight its role in controlling fear, anxiety, and stress, all of which are risk factors for psychiatric diseases. Consequently, multiple efforts have been made to understand the amygdala’s role in the pathophysiology of these conditions. The basolateral amygdala, a key part of the amygdala, is composed of glutamatergic pyramidal neurons that project excitatory signals to the prefrontal cortex, hippocampus, and reward-related regions. It also receives inputs from various systems, including dopaminergic, serotoninergic, and cholinergic pathways. These extensive connections with other brain areas contribute to its role in regulating emotions and its involvement in psychiatric conditions such as schizophrenia, depression, and Alzheimer’s disease. This review explores the role of the amygdala, with a focus on the particularly the basolateral amygdala, in various conditions, including depression (a stress-related disorder), schizophrenia (a neurodevelopmental disorder), dementia (an age-related neurodegenerative disorder), physiological aging, and other psychiatric conditions such as obsessive-compulsive disorder and substance use disorder (including ethanol, hallucinogens, cannabis, stimulants, opioids, and nicotine). The data discussed include potential biomarkers for structural changes in the amygdala documented from clinical studies, as well as animal models relevant to the study of each condition.
Bibliographic Details
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know